10-K: WEED, Inc. Files 10-K Report: Focus Remains on Cannabis Research Amidst Financial Challenges

WEED, Inc.'s 10-K filing reveals ongoing efforts in cannabis research and development, underscored by persistent financial constraints and a need for additional funding.

Summary

• WEED, Inc., formerly United Mines, Inc., is focused on cannabis research and development, aiming to become a global seed-to-sale company.
• The company's strategy includes cannabis genomic studies, development of cannabis-derived compounds, and potential entry into the hemp and infused beverage market.
• WEED, Inc. has a history of operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• The company needs additional financing to complete its cannabis genomic study, enter the hemp and infused beverage market, and fund its operations.
• WEED, Inc. is working on several business opportunities in the cannabis and hemp field, including indoor and outdoor grows, cultivations, and harvest for research, product development, and processing.
• The company completed the purchase of the Sugar Hill Golf course property in Portland, New York, with plans to utilize it for the hemp and infused beverage markets.
• WEED Australia Ltd. was established to conduct cannabis and hemp research and potentially develop products and educational services in Australia.
• Sangre AT, LLC, a wholly-owned subsidiary, is focused on the development and application of cannabis-derived compounds for the treatment of human disease and animal ailments.
• WEED Israel Cannabis Ltd. was formed to conduct clinical trials and product development in Israel, but requires additional funding to proceed.
• The company faces risks related to its limited operating history, capital needs, the evolving legal landscape of the cannabis industry, and competition.
• WEED, Inc. had a comprehensive net loss of $509,917 for the year ended December 31, 2024, compared to a loss of $25,981 in 2023.
• The company's total assets decreased by $165,696 as of December 31, 2024, compared to December 31, 2023, while total liabilities increased by $310,619.
• WEED, Inc. had cash available of $159,355 as of December 31, 2024, and a monthly cash flow burn rate of approximately $45,000.
• The company's management has identified material weaknesses in its internal control over financial reporting.
• Glenn E. Martin serves as President, CEO, and CFO, while Nicole M. Breen serves as Secretary and Treasurer.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company is pursuing promising research and development opportunities in the cannabis industry, it faces significant financial challenges, including operating losses, negative cash flows, and a need for additional funding. The presence of material weaknesses in internal control over financial reporting further contributes to a negative sentiment.

Positives

• WEED, Inc. has acquired property in New York with unlimited water extraction rights, potentially providing an advantage in the hemp and infused beverage markets.
• The company has established subsidiaries in Australia and Israel to pursue international research and development opportunities.
• WEED, Inc. has assembled a team of scientists and researchers to conduct cannabis genomic studies.
• The company owns or controls over 250 cultivars from 1970 Landrace Strains for research purposes.

Negatives

• WEED, Inc. has a history of operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• The company needs additional financing to complete its cannabis genomic study, enter the hemp and infused beverage market, and fund its operations.
• WEED, Inc. had a comprehensive net loss of $509,917 for the year ended December 31, 2024.
• The company's total assets decreased by $165,696 as of December 31, 2024, while total liabilities increased by $310,619.
• Management has identified material weaknesses in internal control over financial reporting.
• The company has a limited operating history and has not generated any revenue since its inception.

Risks

• WEED, Inc. faces risks related to its limited operating history, capital needs, and the evolving legal landscape of the cannabis industry.
• The company's proposed business is dependent on laws pertaining to the cannabis industry, which are subject to change.
• WEED, Inc. faces strong opposition from large, well-funded businesses, including the pharmaceutical industry.
• The company may be unable to adequately protect its proprietary rights.
• WEED, Inc. may be involved in litigation in the future.
• The company's common stock has been thinly traded and may be subject to penny stock rules.
• The company's management has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company plans to research and possibly enter the hemp and infused beverage industry and conduct Sangres Cannabis Genomic Study and process those results, with a long-term goal of becoming a company focused on purchasing land and building commercial grade Cultivation Centers.

Management Comments

• Management believes it is more likely than not that the net deferred tax assets will not be fully realizable.
• Management is actively pursuing new products and services to begin generating revenues.
• Management is currently seeking additional sources of capital to fund short term operations.

Industry Context

The cannabis industry is an emerging industry with many new entrants, with some of them focused on research, some on medicinal cannabis and others focused on cannabis for legal, adult use, i.e. recreational use.

Comparison to Industry Standards

• The document mentions several competitors in the cannabis industry, including Canopy Growth Corporation, Aurora Corporation, Cronos Group, Trulieve Cannabis Corp., TerrAscend Corporation, and Tilray Brands, Inc.
• These companies are involved in various aspects of the cannabis industry, including research, medicinal cannabis, and recreational adult use.
• WEED, Inc. aims to compete in the research and medicinal cannabis segment, focusing on studying and sequencing cannabis DNA to create medicines.
• The company believes its research team's experience, dedicated research space, advanced instrumentation, and custom bioinformatics will allow it to compete favorably.

Legal Proceedings

• The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business.

Related Party Transactions

• The company has received short term loans from officers and directors.
• The company leases its executive offices from Glenn E. Martin, its President.
• The company issued shares of common stock to officers and directors as compensation for services.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity financings.
• Employees and consultants face uncertainty due to the company's financial constraints.
• The company's ability to execute its business plans and achieve its long-term goals is dependent on securing additional funding.

Next Steps

• The company plans to research and possibly enter the hemp and infused beverage industry.
• The company plans to conduct Sangres Cannabis Genomic Study and process those results.
• The company plans to continue seeking additional sources of capital to fund operations.

Key Dates

Keywords

cannabis, hemp, genomic study, research and development, seed-to-sale, financials, WEED Inc, BUDZ, 10-K, operating loss